Suchergebnisse - "Hill, Andrew"

PubPharm (62)

1

Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052) : a randomised, open-label, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2019

von Venter, W. | Moorhouse, M. | Sokhela, S. | +15

CommentIn: Lancet HIV. 2019 Jul;6(7):e412-e413. - PMID 31202689

2

Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women

enthalten in: AIDS reviews | 2017

von Khoo, S. | Peytavin, G. | Burger, D. | +5

3

Choice of antiretroviral drugs for continued treatment scale-up in a public health approach : what more do we need to know?

enthalten in: Journal of the International AIDS Society | 2016

von Vitoria, M. | Hill, A. | Ford, N. | +3

4

Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients : a medium-term follow-up

enthalten in: The Journal of antimicrobial chemotherapy | 2015

von Lanzafame, M. | Lattuada, E. | Rigo, F. | +3

CommentOn: J Antimicrob Chemother. 2014 Sep;69(9):2489-98. - PMID 24821595

5

Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials

enthalten in: HIV clinical trials | 2014

von Powderly, W. | Hill, A. | Moecklinghoff, C.

6

No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial

enthalten in: PloS one | 2014

von Solomon, A. | Tennakoon, S. | Leeansyah, E. | +5

7

Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?

enthalten in: AIDS reviews | 2013

von Ripamonti, D. | Hill, A. | Lauthouwers, E. | +2

8

Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial

enthalten in: International journal of STD & AIDS | 2013

von Arribas, J. | Pulido, F. | Hill, A. | +2

9

Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain

enthalten in: Enfermedades infecciosas y microbiologia clinica | 2013

von Smets, E. | Brogan, A. | Hill, A. | +5

10

Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial

enthalten in: HIV clinical trials | 2013

von Geretti, A. | Arribas, J. | Lathouwers, E. | +6

1
2
3
4
5
6
7
Nächster »
[7]